Nephrocare Health Services Ltd is a leading provider of comprehensive dialysis care in India, offering a range of services from diagnosis to treatment and wellness programs. Their network of clinics provides haemodialysis, home dialysis, and mobile dialysis services, supported by a pharmacy.
The company is India's largest dialysis service provider, serving 29,281 patients and completing 2,885,450 treatments in India in Fiscal 2025. This represents approximately 10% of the total dialysis patients in India. By September 30, 2025, the company had served 31,046 patients and completed 1,591,377 treatments in India.
Nephrocare Health Services Ltd is not only the largest dialysis service provider in India but also in Asia and the fifth largest globally. The company has a global network of 519 clinics, including 51 clinics internationally across the Philippines, Uzbekistan, and Nepal.
The company's IPO valuation is at a P/E of 60.2x with an EV/EBITDA of 26x to its FY25 earnings and a market cap of ₹ 46,153 million post-issue of equity shares. Based on this, the IPO is considered fully priced, and a Subscribe Long Term rating is recommended.
The views and investment tips expressed are those of the investment experts and not of the website or its management. It is advised to check with certified experts before taking any investment decisions.
Key terms: dialysis care, haemodialysis, home dialysis, mobile dialysis, pharmacy, dialysis service provider, IPO valuation, P/E, EV/EBITDA, market cap, Subscribe Long Term
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join Telegram